Nutritional supplements that may be helpful: People diagnosed
with depression may have lower blood levels of omega-3
fatty acids.4 5 A double-blind trial found that bipolar patients taking
9.6 grams of omega-3 fatty acids from fish oil per day in
addition to their conventional medications had significant improvements compared with those
taking placebo.6
L-tryptophan is the amino acid used by the body to
produce serotonin, a chemical messenger important for proper brain function. Supplementation
with L-tryptophan has led to improvement in depression in many studies,7
8 but information is limited about its effect on bipolar disorder. Case reports on two
bipolar patients treated with lithium or an antidepressant drug described marked improvements when they
were given 12 grams daily of L-tryptophan.9 10 Two trials using 6 grams
of L-tryptophan daily for acute mania in patients with bipolar disorder found little or no
improvement,11 12 but another double-blind, controlled study using 9.6
grams daily reported better results.13
L-tryptophan is converted to 5-hydroxytryptophan (5-HTP)
before it becomes serotonin in the body. In a controlled trial, 200 mg daily of supplemental
5-HTP had antidepressant effects in bipolar patients, though it was not as effective as
lithium.14 In a double-blind trial, patients with bipolar disorder had greater
improvement with a combination of 5-HTP at 300 mg daily plus an antidepressant drug than with
5-HTP alone.15
S-adenosylmethionine (SAMe) is another amino acid that has
an impact on serotonin levels, and it has demonstrated significant antidepressant effects in
clinical trials.16 17 18 In both controlled and preliminary
studies, SAMe has been shown to be helpful for the depressive symptoms of bipolar disorder.
However, some patients have switched from depression to mania while using SAMe at 500 to 1,600
mg daily.19 20 This is a known side effect of other antidepressant
medications.21 The mania induced by SAMe resolved when the supplement was
discontinued, and in one case resolved spontaneously while the patient continued taking
SAMe.22 Therefore, people with bipolar disorder should supplement with SAMe only
under the supervision of a qualified healthcare practitioner.
Both folic acid and
vitamin B12 are used in the body to manufacture serotonin and other neurotransmitters. It
is well known that deficiency of either nutrient is associated with depression.23
24 There is some evidence that patients diagnosed with mania are also more likely
to have folate deficiencies than healthy controls.25 Other studies, however, have
found that folic acid deficiency was not more common in bipolar patients taking lithium than
in healthy people.26 27 28 Some studies have found that
people who take lithium long term, and who also have high blood levels of folic acid, respond
better to lithium.29 30 Not all studies have confirmed these findings,
however.31 A double-blind study of patients receiving lithium therapy showed that
the addition of 200 mcg of folic acid per day resulted in clinical improvement, whereas
placebo did not.32
There have been case reports of both mania and depression associated with vitamin B12
deficiency, and these symptoms cleared after treatment with injections of B12.33
34 However, B12 deficiency has not been reported in bipolar disorder patients, and
no studies have been published investigating the effects of vitamin B12 supplementation in
people with bipolar disorder.
Vitamin C helps the body to reduce its load of vanadium
and this has been studied for its possible role in treatment of bipolar disorder.35
A double-blind trial found that both manic and depressed bipolar patients were significantly
improved after one-time administration of 3 grams of vitamin C, compared with a
placebo.36 The same study found that both manic and depressed patients did better
on a reduced-vanadium diet compared to a normal diet. Another double-blind study reported that
4 grams per day of vitamin C in combination with a drug known as EDTA (which also helps remove
elements such as vanadium from the body) was helpful to depressed bipolar patients but not to
those experiencing mania.37 Until more is known, people with bipolar illness should
avoid supplements containing vanadium and consider supplementing with vitamin C.
Inositol is a nutrient found in large amounts in the
brain, but its possible role in mood disorders is unclear. Inositol levels may be reduced in
certain parts of the brains of depressed and bipolar patients.38 However, lithium
reduces normal brain levels of inositol, and this may be one of the ways lithium helps people
with bipolar disorder.39 40 41 Although inositol is known to
have significant antidepressant properties when administered in large amounts of 12 grams per
day,42 43 case reports involving bipolar patients have reported either
no benefit,44 some benefit,45 or worsening of symptoms from inositol
supplementation.46 Until controlled research clarifies the effects of inositol in
people with bipolar illness, it should only be used under the supervision of a qualified
healthcare practitioner.
Acetylcholine levels in the brain may affect mood disorders, and supplemental choline can increase acetylcholine levels. In a preliminary trial,
six people with bipolar disorder were given 1 to 2 grams of choline twice per day (2 to 4
grams per day). Five of the six had a significant reduction in manic symptoms, and four of the
six had a reduction in all mood symptoms.47 No properly controlled trials have yet
investigated the effects of choline in treating people with bipolar disorder.
Restriction of dietary calcium was reported to alleviate
manic episodes in one bipolar patient, and calcium supplementation (approximately 800 mg per
day) increased mania symptoms slightly in six manic-depressive patients, according to another
uncontrolled report.48 Therefore, if calcium supplementation is desired by people
with bipolar disorder, it should be taken with caution.
Lithium is a mineral contained in certain drugs used in
the medical treatment of bipolar disorder. Lithium may be present in some trace mineral
supplements, but amounts are too small to have any effect on bipolar disorder.
Vanadium is a trace mineral nutrient that may adversely
influence bipolar disorder. Elevated blood and hair levels of vanadium have been reported in
people with mania and depression, and one effect of the bipolar medication lithium is to
interrupt a biochemical action of vanadium in the body.49 Vanadium is therefore one
suspect in the search for a cause of bipolar disorder. People with bipolar disorder should
avoid supplements containing vanadium until more is known.
In a preliminary trial, 11 patients with bipolar disorder were treated for six months with
a moderate-potency vitamin-mineral formula (E.M. Power+ manufactured by Evince International,
of Farmington, Utah) that also contained a proprietary blend of amino acids and other
nutrients. The severity of depression decreased on average by 71% and the severity of mania
decreased by 60% during the study.50 A double-blind study is needed to confirm
these promising results.
Are there any side effects or interactions? Refer to the individual herb for
information about any side effects or interactions.
References:
1. Ransford CP. A role for amines in the antidepressant effect of
exercise: a review. Med Sci Sports Exerc 1982;14:1–10 [review].
2. Lykouras E, Garelis E, Varsou E, Stefanis CN. Physical activity and
plasma cyclic adenosine monophosphate levels in manic-depressive patients and healthy adults.
Am J Psychiatry 1979;136:540–2.
3. Norman TC, Mathews W, Yohe CD. A case study on the effects of
strenuous exercise on serum lithium levels. Nebr Med J 1987;72:224–5.
4. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to
eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of
depression. Lipids 1996;31 Suppl:S157–61.
5. Maes M, Christophe A, Delanghe J, et al. Lowered omega 3
polyunsaturated fatty acids in serum phospholipids and cholesterol esters of depressed
patients. Psychiatry Res 1999;85:275–91.
6. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in
bipolar disorder. A preliminary double-blind, placebo-controlled trial. Arch Gen
Psychiatr 1999;56:407–12.
7. Young SN. Behavioral effects of dietary neurotransmitter precursors:
basic and clinical aspects. Neurosci Biobehav Rev 1996;20:313–23 [review].
8. Riemann D, Vorderholzer U. Treatment of depression and sleep
disorders. Significance of serotonin and L-tryptophan in pathophysiology and therapy.
Fortschr Med 1998;116:40–2 [review].
9. Chouinard G, Jones BD, Young SN, Annable L. Potentiation of lithium by
tryptophan in a patient with bipolar illness. Am J Psychiatry
1979;136:719–20.
10. Hedaya RJ. Pharmacokinetic factors in the clinical use of tryptophan.
J Clin Psychopharmacol 1984;4:347–8.
11. Prange AJ, Wilson IC, Lynn CW, et al. L-tryptophan in mania:
contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry
1974;30:56–62.
12. Chambers CA, Naylor GJ. A controlled trial of L-tryptophan in mania.
Br J Psychiatry 1978;132:555–9.
13. Murphy DL, Maker M, Goodwin FK, et al. L-tryptophan in affective
disorders: indoleamine changes and differential clinical effects. Psychopharmacologia
1974;34:11–20.
14. van Praag HM, de Haan S. Chemoprophylaxis of depressions. An attempt
to compare lithium with 5-hydroxytryptophan. Acta Psychiatr Scand Suppl
1981;290:191–201.
15. Mendlewicz J, Youdim MB. Antidepressant potentiation of
5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord
1980;2:137–46.
16. Rosenbaum JF, Fava M, Faulk WE, et al. The antidepressant potential
of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432–6.
17. Friedel HA, Goa KL, Benfield P. S-Adenosyl-l-methionine: A review of
its pharmacological properties and therapeutic potential in liver dysfunction and affective
disorders in relation to its physiological role in cell metabolism. Drugs
1989;38:389–417 [review].
18. Carney MWP, Chary TKN, Bottiglieri T. The switch mechanism in
affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry
1987;150:724–5.
19. Carney MWP, Chary TKN, Bottiglieri T. The switch mechanism in
affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry
1987;150:724–5.
20. Carney MWP, Chary TKN, Bottiglieri T, Reynolds EH. The switch
mechanism and bipolar/unipolar dichotomy. Br J Psychiatry 1989;154:48–51.
21. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the
course of affective illness? Am J Psychiatry 1987;144:1403–11.
22. Rosenbaum JF, Fava M, Faulk WE, et al. The antidepressant potential
of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432–6.
23. Botiglieri T. Folate, vitamin B12, and neuropsychiatric disorders.
Nutr Rev 1996;54:382–90 [review].
24. Fine EJ, Soria ED. Myths about vitamin B12 deficiency. Southern
Med J 1991;84:1475–81.
25. Hasanah CI, Khan UA, Musalmah M, Razali SM. Reduced red-cell folate
in mania. J Affect Disord 1997;46:95–9.
26. McKeon P, Shelley R, O’Regan S, O’Broin J. Serum and red
cell folate and affective morbidity in lithium prophylaxis. Acta Psychiatr Scand
1991;83:199–201.
27. Lee S, Chow CC, Shek CC, et al. Folate concentration in Chinese
psychiatric outpatients on long-term lithium treatment. J Affect Disord
1992;24:265–70.
28. Stern SL, Brandt JT, Hurley RS, et al. Serum and red cell folate
concentrations in outpatients receiving lithium carbonate. Int Clin Psychopharmacol
1988;3:49–52.
29. Coppen A, Abou-Saleh MT. Plasma folate and affective morbidity during
long-term lithium therapy. Br J Psychiatry 1982;141:87–9.
30. Lee S, Chow CC, Shek CC, et al. Folate concentration in Chinese
psychiatric outpatients on long-term lithium treatment. J Affect Disord
1992;24:265–70.
31. Stern SL, Brandt JT, Hurley RS, et al. Serum and red cell folate
concentrations in outpatients receiving lithium carbonate. Int Clin Psychopharmacol
1988;3:49–52.
32. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium
prophylaxis. J Affect Disord 1986;10:9–13.
33. Goggans FC. A case of mania secondary to vitamin B12 deficiency.
Am J Psychiatry 1984;141:300–1.
34. Verbanck PM, LeBon O. Changing psychiatric symptoms in a patient with
vitamin B12 deficiency. J Clin Psychiatry 1991;52:182–3 [letter].
35. Naylor GJ. Vanadium and manic depressive psychosis. Nutr
Health 1984;3:79–85 [review].
36. Naylor GJ, Smith AH. Vanadium: a possible aetiological factor in
manic depressive illness. Psychol Med 1981;11:249–56.
37. Kay DS, Naylor GJ, Smith AH, Greenwood C. The therapeutic effect of
ascorbic acid and EDTA in manic-depressive psychosis: double-blind comparisons with standard
treatments. Psychol Med 1984;14:533–9.
38. Shimon H, Agam G, Belmaker RH, et al. Reduced frontal cortex inositol
levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J
Psychiatry 1997;154:1148–50.
39. Fauroux CM, Freeman S. Inhibitors of inositol monophosphatase. J
Enzyme Inhib 1999;14:97–108 [review].
40. Belmaker RH, Agam G, van Calker D, et al. Behavioral reversal of
lithium effects by four inositol isomers correlates perfectly with biochemical effects on the
PI cycle: depletion by chronic lithium of brain inositol is specific to hypothalamus, and
inositol levels may be abnormal in postmortem brain from bipolar patients.
Neuropsychopharmacology 1998;19:220–32 [review].
41. Belmaker RH, Bersudsky Y, Agam G, et al. How does lithium work on
manic depression? Clinical and psychological correlates of the inositol theory. Annu Rev
Med 1996;47:47–56 [review].
42. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial
of inositol treatment of depression. Am J Psychiatry 1995;152:792–4.
43. Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse
analysis of an inositol study of depression. Isr J Psychiatry Relat Sci
1995;32:14–21.
44. Souza FG, Mander AJ, Foggo M, et al. The effects of lithium
discontinuation and the non-effect of oral inositol upon thyroid hormones and cortisol in
patients with bipolar affective disorder. J Affect Disord 1991;22:165–70.
45. Grisaru N, Belmaker RH. Lithium dosage and inositol levels. Br J
Psychiatry 1994;164:133–4 [letter].
46. Levine J, Witztum E, Greenberg BD, Barak Y. Inositol-induced mania?
Am J Psychiatry 1996;153:839 [letter].
47. Stoll AL, Sachs GS, Cohen MB, et al. Choline in the treatment of
rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated
patients. Biol Psychiatry 1996;40:382–8.
48. Carman JS, Wyatt RJ. Calcium: bivalent cation in the bivalent
psychoses. Biol Psychiatry 1979;14:295–336 [review].
49. Naylor GJ. Vanadium and manic depressive psychosis. Nutr
Health 1984;3:79–85 [review].
50. BJ, Simpson JSA, Ferre RC, et al. Effective mood stabilization with a
chelated mineral supplement: an open-label trial in bipolar disorder. J Clin
Psychiatry 2001;62:936–44.